How to Kill Antibiotic-Resistant ‘Superbugs’ Without Antibiotics
edgylabs.com
edgylabs.com
I looked up the core molecule 'PAMAM' or Poly(amidoamine) and it seems to show relatively low cytoxicity, but recent studies seem to shed some more light:
'More recently, a series of studies by Mukherjee et al.[13][14][15] have shed some light on the mechanism of PAMAM cytotoxicity, providing evidence that the dendrimers break free of their encapsulating membrane (endosome) after being absorbed by the cell, causing harm to the cell's mitochondria and eventually leading to cell death. Further elucidation of the mechanism of PAMAM cytotoxicity would help resolve the dispute as to precisely how toxic the dendrimers are.'
here is a quote though from one paper in mice at high concentrations: 'There was no effect on other haematological parameters. Histopathological evaluation of dendrimer-treated groups did not reveal any abnormalities in the low- and medium-dose groups, but at a high dose level, toxicity was observed in the liver and kidney.'
http://rspa.royalsocietypublishing.org/content/466/2117/1535
http://www.nature.com.sci-hub.ac/articles/nmicrobiol2016162
Please support Sci-Hub: https://sci-hub.ac/donate
These star nanoparticles were termed ‘structurally nanoengineered
antimicrobial peptide polymers’ (SNAPPs). Unlike existing selfassembled
antimicrobial macromolecules, which will dissociate to
unimers below their critical micelle concentration, SNAPPs
are stable unimolecular architectures up to infinite dilution. We
demonstrate that SNAPPs exhibit superior antibacterial activity
against a range of clinically important Gram-negative bacteria,
possess high therapeutic indices and display selectivity towards
pathogens over mammalian cells.
More on biocompatibility with humans: As a test of biocompatibility, the haemolytic activities of SNAPPs
were investigated by incubating them with red blood cells at different
nanoparticle concentrations. Both S16 and S32 had negligible
haemolytic activity. Even at a very high concentration of >100 × MBC,
the extent of haemolysis was well below 30%. Subsequently, we
investigated the viability of two types of mammalian cells (human
embryonic kidney cells and rat hepatoma cells) in response to SNAPPs.
The therapeutic indices (TI) of SNAPPs ranged from 52 to 171 ,
generally higher than the TI of colistin, which is currently being
used as the last therapeutic option for MDR Gram-negative pathogens
Very promising stuff. Even though this was built as a treatment for
gram-negative bacteria, it seems to show an effect for gram-positive
bacteria, too. Equally promising is how uniformly effective SNAPPs
seemed to be across several types of gram-negative bacteria.Also, the mechanism of action is one which bacteria would have a very hard time learning resistance to.
megaplate: https://player.vimeo.com/video/180908160
It's a bit early for that, isn't it? Give it a decade or two of widespread use, and then we'll see.
> Also, the mechanism of action is one which bacteria would have a very hard time learning resistance to.
That is hopeful. But how hard is "a very hard time"? It takes decades? Centuries? Or never?
This would require evolution of the outer membrane (OM), quite a big change for a bacteria to evolve. That said it's very surprising there are so few off target effects.
A good example is highly acid/basic environments, thermal stress, or alcohols and solvents.
Anything that can reproduce in a 50 degree C alcohol bath, for example, is going to have a tough time adapting to humans well enough to be pathogenic.
These polymers might be a similar phenomenon, but that would also imply that they're inimical to humanity too, though perhaps at a higher concentration.
Sterilization protocols need to be followed to ensure that one patients prions don't infect another surgery patient. It turns out that relatively recent concerns over transmissible spongiform encephalopathy, caused by prions, has required changes to the sterilization procedures used in hospitals.
For example, nearly all antibiotics and antifungals target cell walls - a clear distinction that mammalian cells lack.
I wouldn't want a treatment for my cold that could give me cancer in 20 years...
Please don't take antibiotics to treat viral infections. The best you can hope for is (measurable) damage to your own gut bacteria. The worst is breeding more superbugs.
Therefore many (though certainly not all) colds are appropriately treated with an antibiotic.
And while I guess it isn't entirely understood, the dose seems to matter with asbestos (the resulting diseases are often categorized as occupational).
Unconstrained use of antibiotics allow bacteria's natural defenses to learn how to stay alive in our bodies.
A bacterium does a series of chemical transformations to stay alive.
An antibiotic disrupts the bacteria lifecycle by interfering with such transformations.
These transformations might be different across bacteria. As you have millions of bacteria in an individual, some might suffer smaller results from the antibiotic, and be 'not as disrupted'.
If you don't take the full dose of antibiotics, these 'not as disrupted' bacteria might survive, make you sick again. And worse: the antibiotic will have a harder time killing them.
Some of their 'children' will be more 'disruptable' then they are, some less, but the average is less 'disruptable'.
Repeat the process many times, and you get bacteria that don't die with the antibiotic :(
Nothing to do with your immune system, that creates its own kind of 'antibiotic'
If there are you could attack it with a coctail of two or three.
Why aren't phages being researched?
Does this target mitochondria too? Other bacteriocidal antibiotics apparently do so, because the structures are similar enough.
Phage therapy is neat, it really is, but there are a couple major issues:
- There is no such thing as a "broad spectrum" phage. You can't do empirical treatment using phages, and there's not really "off the shelf" phage therapy - it tends to be a bespoke creation for a particular infection.
- There's some serious regulatory problems, similar to those experienced by fecal transplant treatments. We're not yet really equipped to think about handling evolving, custom microbes as a treatment. - Because of the first, it's going to require a considerable amount more lab capacity than most clinical settings currently have, and considerable delays until treatment.
- There's also some biosafety issues around phage prep, but those are easily solvable.
It's a great way to treat particularly resistant or hard to treat infections, but it's not a particularly great general solution. There's a reason it was abandoned in countries with easy access to antibiotics - they're just roundly superior in basically every respect.
Or would that be unrealistic as of 2016?